Acasti Pharma Inc. (SEC Filing Page | XBRL Cloud Viewer | XBRL Instance)

Line Label Object Class Period Type Balance Report ElementName
1 000 - Document - Document And Entity Information Network

*

*

 http://www.acastipharma.com/20180331/role/statement-document-and-entity-information
2 Document Information [Table] Table

*

*

 dei:DocumentInformationTable
3 Legal Entity [Axis] Axis dei:LegalEntityAxis
4 Entity [Domain] Member dei:EntityDomain
5 Document Information [Line Items] LineItems dei:DocumentInformationLineItems
6 Entity Registrant Name Concept (Text/String) For Period dei:EntityRegistrantName
7 Entity Central Index Key Concept (CIK Number) For Period dei:EntityCentralIndexKey
8 Trading Symbol Concept (Text/String) For Period dei:TradingSymbol
9 Current Fiscal Year End Date Concept (Month/Day) For Period dei:CurrentFiscalYearEndDate
10 Entity Filer Category Concept (Filer Category) For Period dei:EntityFilerCategory
11 Entity Current Reporting Status Concept (Yes/No) For Period dei:EntityCurrentReportingStatus
12 Entity Voluntary Filers Concept (Yes/No) For Period dei:EntityVoluntaryFilers
13 Entity Well-known Seasoned Issuer Concept (Yes/No) For Period dei:EntityWellKnownSeasonedIssuer
14 Entity Common Stock, Shares Outstanding (in shares) Concept (Shares) As Of dei:EntityCommonStockSharesOutstanding
15 Document Type Concept (Submission Type) For Period dei:DocumentType
16 Document Period End Date Concept (Date) For Period dei:DocumentPeriodEndDate
17 Document Fiscal Year Focus Concept (Year) For Period dei:DocumentFiscalYearFocus
18 Document Fiscal Period Focus Concept (Fiscal Period) For Period dei:DocumentFiscalPeriodFocus
19 Amendment Flag Concept (Yes/No) For Period dei:AmendmentFlag
20 001 - Statement - Statements of Financial Position (February 2017 Unaudited) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-statements-of-financial-position-february-2017-unaudited-
21 Statement Table [Table] Table

*

*

 acst:StatementTable
22 Legal Entity [Axis] Axis dei:LegalEntityAxis
23 Entity [Domain] Member dei:EntityDomain
24 Statement Line Items [Line Items] LineItems acst:StatementLineItems
25 Current assets: Abstract ifrs-full:CurrentAssetsAbstract
26 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
27 Receivables Concept (Monetary) As Of Debit ifrs-full:TradeAndOtherCurrentReceivables
28 Other Assets Concept (Monetary) As Of Debit ifrs-full:OtherCurrentAssets
29 Prepaid expenses Concept (Monetary) As Of Debit ifrs-full:CurrentPrepaidExpenses
30 Total current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
31 Marketable securities Concept (Monetary) As Of Debit ifrs-full:LongtermDeposits
32 Other Asset Concept (Monetary) As Of Debit ifrs-full:OtherNoncurrentAssets
33 Equipment Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
34 Intangible assets Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsAndGoodwill
35 Total assets Concept (Monetary) As Of Debit ifrs-full:Assets
36 Current liabilities Abstract ifrs-full:CurrentLiabilitiesAbstract
37 Trade and other payables Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
38 Total current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
39 Derivative warrant liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentDerivativeFinancialLiabilities
40 Unsecured convertible debentures Concept (Monetary) As Of Credit ifrs-full:DebtSecurities
41 Total liabilities Concept (Monetary) As Of Credit ifrs-full:Liabilities
42 Equity: Abstract ifrs-full:EquityAbstract
43 Share capital Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
44 Other equity Concept (Monetary) As Of Credit ifrs-full:OtherEquityInterest
45 Contributed surplus Concept (Monetary) As Of Credit ifrs-full:AdditionalPaidinCapital
46 Deficit Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
47 Total equity Concept (Monetary) As Of Credit ifrs-full:Equity
48 Commitments and contingencies Concept (Monetary) As Of Credit ifrs-full:CapitalCommitments
49 Total liabilities and equity Concept (Monetary) As Of Credit ifrs-full:EquityAndLiabilities
50 002 - Statement - Statements of Earnings and Comprehensive Loss (Twelve Month and Month Ended 2017 Unaudited) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited
51 Statement Table [Table] Table

*

*

 acst:StatementTable
52 Legal Entity [Axis] Axis dei:LegalEntityAxis
53 Entity [Domain] Member dei:EntityDomain
54 Statement Line Items [Line Items] LineItems acst:StatementLineItems
55 Research and development expenses, net of government assistance Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
56 General and administrative expenses Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
57 Loss from operating activities Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromOperatingActivities
58 Change in fair value of warrant liabilities Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
59 Other financial expenses Concept (Monetary) For Period Credit acst:GrossFinanceIncomeCost
60 Net financial expenses Concept (Monetary) For Period Credit ifrs-full:FinanceIncomeCost
61 Net loss and comprehensive loss before income tax Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeBeforeTax
62 Deferred income tax recovery Concept (Monetary) For Period ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
63 Net loss and total comprehensive loss Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
64 Basic and diluted loss per share (in CAD per share) Concept (Share) For Period ifrs-full:BasicAndDilutedEarningsLossPerShare
65 Weighted average number of shares outstanding (in shares) Concept (Shares) For Period ifrs-full:WeightedAverageShares
66 003 - Statement - Statements of Changes in Equity (Twelve Month and Month Ended 2017 Unaudited) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited
67 Statement Table [Table] Table

*

*

 acst:StatementTable
68 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
69 Equity [member] Member ifrs-full:EquityMember
70 Issued capital [member] Member ifrs-full:IssuedCapitalMember
71 Other equity interest [member] Member ifrs-full:OtherEquityInterestMember
72 Additional paid-in capital [member] Member ifrs-full:AdditionalPaidinCapitalMember
73 Retained earnings [member] Member ifrs-full:RetainedEarningsMember
74 Statement Line Items [Line Items] LineItems acst:StatementLineItems
75 Net loss and total comprehensive loss for the period Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
76 Concept (Monetary) As Of Credit acst:NetEquity
77 Transactions with owners, recorded directly in equity Abstract acst:TransactionsWithOwnersRecordedDirectlyInEquityAbstract
78 Issuance of shares (in shares) Concept (Shares) For Period acst:IssueOfEquityNumberOfShares
79 Issuance of shares Concept (Monetary) For Period Credit ifrs-full:IssueOfEquity
80 Warrants exercised (in shares) Concept (Shares) For Period acst:WarrantsExercisedEquitySharesIssued
81 Warrants exercised Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
82 Share-based payment transactions for the period Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
83 Number of shares (in shares) Concept (Shares) For Period acst:ConversionOfConvertibleInstrumentsEquitySharesIssued
84 Amount Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
85 Total contributions by and distributions to equity holders (in shares) Concept (Shares) For Period ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
86 Total contributions by and distributions to equity holders Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
87 Balance (in shares) Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
88 Balance Concept (Monetary) As Of Credit ifrs-full:Equity
89 Net loss and total comprehensive loss for the period Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
90 Concept (Monetary) As Of Credit acst:NetEquity
91 Issue of unsecured convertible debentures, net of deferred income tax expense of $129 income tax expense of $129 Concept (Monetary) For Period Credit ifrs-full:IssueOfConvertibleInstruments
92 Equity settled non-employee share-based payment (in shares) Concept (Shares) For Period acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares
93 Equity settled non-employee share-based payment Concept (Monetary) For Period Credit acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment
94 Balance (in shares) Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
95 Balance Concept (Monetary) As Of Credit ifrs-full:Equity
96 Share options exercised (in shares) Concept (Shares) For Period acst:NumberOfSharesIssuedStockOptionsExercised
97 Share options exercised Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
98 RSUs released (in shares) Concept (Shares) For Period acst:NumbersOfSharesIssuedRestrictedStockUnits
99 RSUs released Concept (Monetary) For Period Credit acst:IncreaseDecreaseInEquityFromTheReleaseOfRestrictedStockUnits
100 004 - Statement - Statements of Changes in Equity (Twelve Month and Month Ended 2017 Unaudited) (Parentheticals) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals
101 Statement Table [Table] Table

*

*

 acst:StatementTable
102 Statement Line Items [Line Items] LineItems acst:StatementLineItems
103 Deferred income tax recovery Concept (Monetary) For Period ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
104 005 - Statement - Statements of Cash Flows (Twelve Month and Month Ended 2017 Unaudited) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited
105 Statement Table [Table] Table

*

*

 acst:StatementTable
106 Legal Entity [Axis] Axis dei:LegalEntityAxis
107 Entity [Domain] Member dei:EntityDomain
108 Statement Line Items [Line Items] LineItems acst:StatementLineItems
109 Cash flows used in operating activities: Abstract ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract
110 Net loss for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
111 Adjustments: Abstract ifrs-full:AdjustmentsForReconcileProfitLossAbstract
112 Amortization of intangible assets Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForAmortisationExpense
113 Depreciation of equipment Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDepreciationExpense
114 Impairment loss related to intangible assets Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
115 Stock-based compensation Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
116 Net financial expenses Concept (Monetary) For Period Credit ifrs-full:AdjustmentsForFinanceIncomeCost
117 Realized foreign exchange gain (loss) Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
118 Deferred income tax recovery Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDeferredTaxExpense
119 Total adjustments Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForReconcileProfitLoss
120 Changes in working capital items Concept (Monetary) For Period Debit ifrs-full:OtherAdjustmentsForNoncashItems
121 Net cash used in operating activities Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperatingActivities
122 Cash flows from (used in) investing activities: Abstract ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract
123 Interest received Concept (Monetary) For Period Debit ifrs-full:InterestReceivedClassifiedAsInvestingActivities
124 Acquisition of intangible assets Concept (Monetary) For Period Credit ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
125 Acquisition of equipment Concept (Monetary) For Period Credit ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
126 Acquisition of short-term investments Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
127 Acquisition of marketable securities Concept (Monetary) For Period Credit ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
128 Maturity of short-term investments Concept (Monetary) For Period Debit ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
129 Net cash (used in) investing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInInvestingActivities
130 Cash flows from (used in) financing activities: Abstract ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
131 Net proceeds from public offering Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
132 Net proceeds from private placement Concept (Monetary) For Period Debit acst:ProceedsFromIssuingSharesPrivatePlacement
133 Proceeds from exercise of warrants Concept (Monetary) For Period Debit acst:ProceedsFromExerciseOfWarrants
134 Share issue costs Concept (Monetary) For Period Credit ifrs-full:PaymentsForShareIssueCosts
135 Interest paid Concept (Monetary) For Period Credit ifrs-full:InterestPaidClassifiedAsFinancingActivities
136 Net cash from (used in) financing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInFinancingActivities
137 Foreign exchange (loss) gain on cash and cash equivalents held in foreign currencies Concept (Monetary) For Period Debit ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
138 Net increase (decrease) in cash and cash equivalents Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
139 Cash and cash equivalents, beginning of period Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
140 Cash and cash equivalents, end of period Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
141 Cash Concept (Monetary) As Of Debit ifrs-full:Cash
142 Cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashEquivalents
143 006 - Disclosure - Note 1 - Reporting Entity Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-1-reporting-entity
144 Statement Table [Table] Table

*

*

 acst:StatementTable
145 Legal Entity [Axis] Axis dei:LegalEntityAxis
146 Entity [Domain] Member dei:EntityDomain
147 Neptune Technologies and Bioressources Inc. [member] Member acst:NeptuneTechnologiesAndBioressourcesIncMember
148 Associates [axis] Axis ifrs-full:SignificantInvestmentsInAssociatesAxis
149 Entity's total for associates [member] Member ifrs-full:EntitysTotalForAssociatesMember
150 Acasti Pharma Inc. [member] Member acst:AcastiPharmaIncMember
151 Statement Line Items [Line Items] LineItems acst:StatementLineItems
152 Disclosure of basis of consolidation [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBasisOfConsolidationExplanatory
153 007 - Disclosure - Note 2 - Basis of Preparation Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-2-basis-of-preparation-
154 Statement Table [Table] Table

*

*

 acst:StatementTable
155 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
156 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
157 Major ordinary share transactions [member] Member ifrs-full:MajorOrdinaryShareTransactionsMember
158 Legal Entity [Axis] Axis dei:LegalEntityAxis
159 Entity [Domain] Member dei:EntityDomain
160 Statement Line Items [Line Items] LineItems acst:StatementLineItems
161 Disclosure of basis of preparation of financial statements [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
162 008 - Disclosure - Note 3 - Significant Accounting Policies Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-3-significant-accounting-policies
163 Statement Table [Table] Table

*

*

 acst:StatementTable
164 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
165 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
166 FRANCE Member country:FR
167 Legal Entity [Axis] Axis dei:LegalEntityAxis
168 Entity [Domain] Member dei:EntityDomain
169 Statement Line Items [Line Items] LineItems acst:StatementLineItems
170 Disclosure of significant accounting policies [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
171 009 - Disclosure - Note 4 - Receivables Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-4-receivables
172 Statement Table [Table] Table

*

*

 acst:StatementTable
173 Legal Entity [Axis] Axis dei:LegalEntityAxis
174 Entity [Domain] Member dei:EntityDomain
175 Statement Line Items [Line Items] LineItems acst:StatementLineItems
176 Disclosure of trade and other receivables [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory
177 010 - Disclosure - Note 5 - Other Assets Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-5-other-assets
178 Statement Table [Table] Table

*

*

 acst:StatementTable
179 Classes of assets [axis] Axis ifrs-full:ClassesOfAssetsAxis
180 Assets [member] Member ifrs-full:ClassesOfAssetsMember
181 Krill oil [member] Member acst:KrillOilMember
182 Legal Entity [Axis] Axis dei:LegalEntityAxis
183 Entity [Domain] Member dei:EntityDomain
184 Statement Line Items [Line Items] LineItems acst:StatementLineItems
185 Disclosure of other assets [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOtherAssetsExplanatory
186 011 - Disclosure - Note 6 - Related Parties Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-6-related-parties
187 Statement Table [Table] Table

*

*

 acst:StatementTable
188 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
189 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
190 Neptune [member] Member acst:NeptuneMember
191 Parent [member] Member ifrs-full:ParentMember
192 Key management personnel of entity or parent [member] Member ifrs-full:KeyManagementPersonnelOfEntityOrParentMember
193 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
194 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
195 Biodroga Nutraceuticals Inc. [member] Member acst:BiodrogaNutraceuticalsIncMember
196 Maturity [axis] Axis ifrs-full:MaturityAxis
197 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
198 Not later than six months [member] Member acst:NotLaterThanSixMonthsMember
199 Later than six months [member] Member ifrs-full:LaterThanSixMonthsMember
200 Range [axis] Axis ifrs-full:RangeAxis
201 Ranges [member] Member ifrs-full:RangesMember
202 Top of range [member] Member ifrs-full:TopOfRangeMember
203 Legal Entity [Axis] Axis dei:LegalEntityAxis
204 Entity [Domain] Member dei:EntityDomain
205 Statement Line Items [Line Items] LineItems acst:StatementLineItems
206 Disclosure of related party [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfRelatedPartyExplanatory
207 012 - Disclosure - Note 7 - Government Assistance Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-7-government-assistance
208 Statement Table [Table] Table

*

*

 acst:StatementTable
209 Legal Entity [Axis] Axis dei:LegalEntityAxis
210 Entity [Domain] Member dei:EntityDomain
211 Statement Line Items [Line Items] LineItems acst:StatementLineItems
212 Disclosure of government grants [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfGovernmentGrantsExplanatory
213 013 - Disclosure - Note 8 - Equipment Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-8-equipment-
214 Statement Table [Table] Table

*

*

 acst:StatementTable
215 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
216 Carrying amount [member] Member ifrs-full:CarryingAmountMember
217 Gross carrying amount [member] Member ifrs-full:GrossCarryingAmountMember
218 Legal Entity [Axis] Axis dei:LegalEntityAxis
219 Entity [Domain] Member dei:EntityDomain
220 Statement Line Items [Line Items] LineItems acst:StatementLineItems
221 Disclosure of property, plant and equipment [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
222 014 - Disclosure - Note 9 - Intangible Assets Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-9-intangible-assets
223 Statement Table [Table] Table

*

*

 acst:StatementTable
224 Legal Entity [Axis] Axis dei:LegalEntityAxis
225 Entity [Domain] Member dei:EntityDomain
226 Statement Line Items [Line Items] LineItems acst:StatementLineItems
227 Disclosure of intangible assets [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIntangibleAssetsExplanatory
228 015 - Disclosure - Note 10 - Trade and Other Payables Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-10-trade-and-other-payables
229 Statement Table [Table] Table

*

*

 acst:StatementTable
230 Legal Entity [Axis] Axis dei:LegalEntityAxis
231 Entity [Domain] Member dei:EntityDomain
232 Statement Line Items [Line Items] LineItems acst:StatementLineItems
233 Disclosure of trade and other payables [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
234 016 - Disclosure - Note 11 - Derivative Warrant Liabilities Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-11-derivative-warrant-liabilities-
235 Statement Table [Table] Table

*

*

 acst:StatementTable
236 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
237 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
238 Warrant liabilities issued December 27, 2017 [member] Member acst:WarrantLiabilitiesIssuedDecember272017Member
239 Warrant liabilities issued December 3, 2013 [member] Member acst:WarrantLiabilitiesIssuedDecember32013Member
240 Legal Entity [Axis] Axis dei:LegalEntityAxis
241 Entity [Domain] Member dei:EntityDomain
242 Statement Line Items [Line Items] LineItems acst:StatementLineItems
243 Disclosure of derivative financial instruments [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory
244 017 - Disclosure - Note 12 - Unsecured Convertible Debentures Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-12-unsecured-convertible-debentures
245 Statement Table [Table] Table

*

*

 acst:StatementTable
246 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
247 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
248 Unsecured convertible debentures [member] Member acst:UnsecuredConvertibleDebenturesMember
249 Legal Entity [Axis] Axis dei:LegalEntityAxis
250 Entity [Domain] Member dei:EntityDomain
251 Statement Line Items [Line Items] LineItems acst:StatementLineItems
252 Disclosure of borrowings [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBorrowingsExplanatory
253 018 - Disclosure - Note 13 - Capital and Other Components of Equity Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-13-capital-and-other-components-of-equity
254 Statement Table [Table] Table

*

*

 acst:StatementTable
255 Classes of share capital [axis] Axis ifrs-full:ClassesOfShareCapitalAxis
256 Share capital [member] Member ifrs-full:ClassesOfShareCapitalMember
257 Class B shares [Member] Member acst:ClassBSharesMember
258 Class C shares [Member] Member acst:ClassCSharesMember
259 Class D and E shares [Member] Member acst:ClassDAndESharesMember
260 Class A shares [member] Member acst:ClassASharesMember
261 Range [axis] Axis ifrs-full:RangeAxis
262 Ranges [member] Member ifrs-full:RangesMember
263 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
264 Top of range [member] Member ifrs-full:TopOfRangeMember
265 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
266 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
267 Class A shares [member] Member acst:ClassASharesMember
268 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
269 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
270 Warrant liabilities issued December 27, 2017 [member] Member acst:WarrantLiabilitiesIssuedDecember272017Member
271 Derivative warrant liabilities [member] Member acst:DerivativeWarrantLiabilitiesMember
272 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
273 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
274 Underwriter [member] Member acst:UnderwriterMember
275 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
276 Counterparties [member] Member ifrs-full:CounterpartiesMember
277 Underwriter [member] Member acst:UnderwriterMember
278 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
279 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
280 Exercised portion of a over-allotment option [member] Member acst:ExercisedPortionOfAOverallotmentOptionMember
281 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
282 Equity [member] Member ifrs-full:EquityMember
283 Additional paid-in capital [member] Member ifrs-full:AdditionalPaidinCapitalMember
284 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
285 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
286 Public offering warrants 2017 related to liability [member] Member acst:PublicOfferingWarrants2017RelatedToLiabilityMember
287 Series 8 December 2013 Public offering warrants related to liability [member] Member acst:Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember
288 Series 2017-BW Broker warrants related to equity [member] Member acst:Series2017BWBrokerWarrantsRelatedToEquityMember
289 Public offering warrants February 2017, equity portion [member] Member acst:PublicOfferingWarrantsFebruary2017EquityPortionMember
290 Series December 2017 US Broker warrants, equity portion [member] Member acst:SeriesDecember2017UsBrokerWarrantsEquityPortionMember
291 The 2017 Unsecured convertible debenture conversion option and contingent warrant related to equity [member] Member acst:The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember
292 Series 9 Private Placement warrants 2013 related to equity [member] Member acst:Series9PrivatePlacementWarrants2013RelatedToEquityMember
293 Legal Entity [Axis] Axis dei:LegalEntityAxis
294 Entity [Domain] Member dei:EntityDomain
295 Statement Line Items [Line Items] LineItems acst:StatementLineItems
296 Disclosure of share capital, reserves and other equity interest [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
297 019 - Disclosure - Note 14 - Personnel Expenses Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-14-personnel-expenses
298 Statement Table [Table] Table

*

*

 acst:StatementTable
299 Legal Entity [Axis] Axis dei:LegalEntityAxis
300 Entity [Domain] Member dei:EntityDomain
301 Statement Line Items [Line Items] LineItems acst:StatementLineItems
302 Disclosure of personnel expenses [text block Concept (Text Block (HTML)) For Period acst:DisclosureOfPersonnelExpensesTextBlock
303 020 - Disclosure - Note 15 - Financial Expenses Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-15-financial-expenses
304 Statement Table [Table] Table

*

*

 acst:StatementTable
305 Legal Entity [Axis] Axis dei:LegalEntityAxis
306 Entity [Domain] Member dei:EntityDomain
307 Statement Line Items [Line Items] LineItems acst:StatementLineItems
308 Disclosure of finance income (cost) [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory
309 021 - Disclosure - Note 16 - Share-based Payments Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-16-sharebased-payments
310 Statement Table [Table] Table

*

*

 acst:StatementTable
311 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
312 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
313 Corporation stock option plan [member] Member acst:CorporationStockOptionPlanMember
314 Corporation equity incentive plan [member] Member acst:CorporationEquityIncentivePlanMember
315 Range [axis] Axis ifrs-full:RangeAxis
316 Ranges [member] Member ifrs-full:RangesMember
317 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
318 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
319 Counterparties [member] Member ifrs-full:CounterpartiesMember
320 Consultants [member] Member acst:ConsultantsMember
321 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
322 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
323 Related parties [member] Member ifrs-full:RelatedPartiesMember
324 Shareholders exceeding 5% issued and outstanding stock [member] Member acst:ShareholdersExceeding5IssuedAndOutstandingStockMember
325 Legal Entity [Axis] Axis dei:LegalEntityAxis
326 Entity [Domain] Member dei:EntityDomain
327 Statement Line Items [Line Items] LineItems acst:StatementLineItems
328 Disclosure of share-based payment arrangements [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
329 022 - Disclosure - Note 17 - Loss Per Share Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-17-loss-per-share
330 Statement Table [Table] Table

*

*

 acst:StatementTable
331 Legal Entity [Axis] Axis dei:LegalEntityAxis
332 Entity [Domain] Member dei:EntityDomain
333 Statement Line Items [Line Items] LineItems acst:StatementLineItems
334 Earnings per share [text block] Concept (Text Block (HTML)) For Period ifrs-full:EarningsPerShareExplanatory
335 023 - Disclosure - Note 18 - Supplemental Cash Flow Disclosure Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-18-supplemental-cash-flow-disclosure
336 Statement Table [Table] Table

*

*

 acst:StatementTable
337 Legal Entity [Axis] Axis dei:LegalEntityAxis
338 Entity [Domain] Member dei:EntityDomain
339 Statement Line Items [Line Items] LineItems acst:StatementLineItems
340 Disclosure of additional information about understanding financial position and liquidity of entity [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory
341 024 - Disclosure - Note 19 - Income Taxes Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-19-income-taxes
342 Statement Table [Table] Table

*

*

 acst:StatementTable
343 Legal Entity [Axis] Axis dei:LegalEntityAxis
344 Entity [Domain] Member dei:EntityDomain
345 Statement Line Items [Line Items] LineItems acst:StatementLineItems
346 Disclosure of income tax [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIncomeTaxExplanatory
347 025 - Document - Note 20 - Financial Instruments Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-20-financial-instruments
348 Statement Table [Table] Table

*

*

 acst:StatementTable
349 Legal Entity [Axis] Axis dei:LegalEntityAxis
350 Entity [Domain] Member dei:EntityDomain
351 Statement Line Items [Line Items] LineItems acst:StatementLineItems
352 Disclosure of financial instruments [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
353 026 - Disclosure - Note 21 - Commitments and Contingencies Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-21-commitments-and-contingencies
354 Statement Table [Table] Table

*

*

 acst:StatementTable
355 Classes of contingent liabilities [axis] Axis ifrs-full:ClassesOfContingentLiabilitiesAxis
356 Contingent liabilities [member] Member ifrs-full:ContingentLiabilitiesMember
357 Research and development projects [member] Member acst:ResearchAndDevelopmentProjectsMember
358 Former CEO [member] Member acst:FormerCEOMember
359 Arrangements involving legal form of lease [axis] Axis ifrs-full:ArrangementsInvolvingLegalFormOfLeaseAxis
360 Arrangements involving legal form of lease [member] Member ifrs-full:ArrangementsInvolvingLegalFormOfLeaseMember
361 Lease for laboratory facility located in Sherbrooke, Québec [member] Member acst:LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember
362 Maturity [axis] Axis ifrs-full:MaturityAxis
363 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
364 Not later than one year [member] Member ifrs-full:NotLaterThanOneYearMember
365 Later than one year and not later than two years [member] Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
366 Legal Entity [Axis] Axis dei:LegalEntityAxis
367 Entity [Domain] Member dei:EntityDomain
368 Statement Line Items [Line Items] LineItems acst:StatementLineItems
369 Disclosure of commitments and contingent liabilities [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
370 027 - Disclosure - Note 22 - Determination of Fair Values Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-22-determination-of-fair-values
371 Statement Table [Table] Table

*

*

 acst:StatementTable
372 Legal Entity [Axis] Axis dei:LegalEntityAxis
373 Entity [Domain] Member dei:EntityDomain
374 Statement Line Items [Line Items] LineItems acst:StatementLineItems
375 Disclosure of fair value measurement [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFairValueMeasurementExplanatory
376 028 - Disclosure - Note 23 - Capital Management Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-23-capital-management
377 Statement Table [Table] Table

*

*

 acst:StatementTable
378 Range [axis] Axis ifrs-full:RangeAxis
379 Ranges [member] Member ifrs-full:RangesMember
380 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
381 Top of range [member] Member ifrs-full:TopOfRangeMember
382 Maturity [axis] Axis ifrs-full:MaturityAxis
383 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
384 Matures on April 11, 2017 [member] Member acst:MaturesOnApril112017Member
385 Matures on April 25, 2017 [member] Member acst:MaturesOnApril252017Member
386 Matures on March 12, 2017 [member] Member acst:MaturesOnMarch122017Member
387 Matures on March 28, 2017 [member] Member acst:MaturesOnMarch282017Member
388 Legal Entity [Axis] Axis dei:LegalEntityAxis
389 Entity [Domain] Member dei:EntityDomain
390 Statement Line Items [Line Items] LineItems acst:StatementLineItems
391 Disclosure of objectives, policies and processes for managing capital [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory
392 029 - Disclosure - Note 24 - Subsequent Event Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-24-subsequent-event
393 Statement Table [Table] Table

*

*

 acst:StatementTable
394 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
395 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
396 Major ordinary share transactions [member] Member ifrs-full:MajorOrdinaryShareTransactionsMember
397 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
398 Counterparties [member] Member ifrs-full:CounterpartiesMember
399 Underwriter [member] Member acst:UnderwriterMember
400 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
401 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
402 Non-transferable broker warrants [member] Member acst:NontransferableBrokerWarrantsMember
403 Broker warrants [member] Member acst:BrokerWarrantsMember
404 Broker warrants expiring on May 9, 2023 [member] Member acst:BrokerWarrantsExpiringOnMay92023Member
405 Broker warrants expiring on May 14, 2023 [member] Member acst:BrokerWarrantsExpiringOnMay142023Member
406 Legal Entity [Axis] Axis dei:LegalEntityAxis
407 Entity [Domain] Member dei:EntityDomain
408 Statement Line Items [Line Items] LineItems acst:StatementLineItems
409 Disclosure of events after reporting period [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
410 030 - Disclosure - Significant Accounting Policies (Policies) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-significant-accounting-policies-policies
411 Statement Table [Table] Table

*

*

 acst:StatementTable
412 Legal Entity [Axis] Axis dei:LegalEntityAxis
413 Entity [Domain] Member dei:EntityDomain
414 Statement Line Items [Line Items] LineItems acst:StatementLineItems
415 Discloure of Significant Accounting Policies Abstract acst:DisclosureOfSignificantAccountingPoliciesAbstract
416 Description of accounting policy for financial instruments [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
417 Description of accounting policy for property, plant and equipment [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
418 Description of accounting policy for intangible assets and goodwill [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory
419 Description of accounting policy for impairment of assets [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory
420 Description of accounting policy for employee benefits [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
421 Description of accounting policy for provisions [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
422 Description of accounting policy for government grants [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants
423 Description of accounting policy for leases [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
424 Description of accounting policy for foreign currency translation [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
425 Description of accounting policy for finance income and costs [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory
426 Description of accounting policy for income tax [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
427 Description of accounting policy for earnings per share [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
428 Description of accounting policy for segment reporting [text block] Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory
429 Description of accounting policy for changes in accounting policy [text block] Concept (Text Block (HTML)) For Period acst:DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock
430 031 - Disclosure - Note 3 - Significant Accounting Policies (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-3-significant-accounting-policies-tables
431 Statement Table [Table] Table

*

*

 acst:StatementTable
432 Legal Entity [Axis] Axis dei:LegalEntityAxis
433 Entity [Domain] Member dei:EntityDomain
434 Statement Line Items [Line Items] LineItems acst:StatementLineItems
435 Disclosure of useful lives and rates [text block] Concept (Text Block (HTML)) For Period acst:DisclosureOfUsefulLivesAndRatesTextBlock
436 032 - Disclosure - Note 4 - Receivables (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-4-receivables-tables
437 Statement Table [Table] Table

*

*

 acst:StatementTable
438 Legal Entity [Axis] Axis dei:LegalEntityAxis
439 Entity [Domain] Member dei:EntityDomain
440 Statement Line Items [Line Items] LineItems acst:StatementLineItems
441 Disclosure of detailed information of trade and other receivables [text block] Concept (Text Block (HTML)) For Period acst:DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock
442 033 - Disclosure - Note 6 - Related Parties (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-6-related-parties-tables
443 Statement Table [Table] Table

*

*

 acst:StatementTable
444 Legal Entity [Axis] Axis dei:LegalEntityAxis
445 Entity [Domain] Member dei:EntityDomain
446 Statement Line Items [Line Items] LineItems acst:StatementLineItems
447 Disclosure of research and development expense [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
448 Disclosure of information about key management personnel [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory
449 034 - Disclosure - Note 7 - Government Assistance (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-7-government-assistance-tables
450 Statement Table [Table] Table

*

*

 acst:StatementTable
451 Legal Entity [Axis] Axis dei:LegalEntityAxis
452 Entity [Domain] Member dei:EntityDomain
453 Statement Line Items [Line Items] LineItems acst:StatementLineItems
454 Disclosure of detailed information about government grants and investment tax credits [text block] Concept (Text Block (HTML)) For Period acst:DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock
455 Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
456 035 - Disclosure - Note 8 - Equipment (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-8-equipment-tables
457 Statement Table [Table] Table

*

*

 acst:StatementTable
458 Legal Entity [Axis] Axis dei:LegalEntityAxis
459 Entity [Domain] Member dei:EntityDomain
460 Statement Line Items [Line Items] LineItems acst:StatementLineItems
461 Disclosure of detailed information about property, plant and equipment [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
462 036 - Disclosure - Note 9 - Intangible Assets (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-9-intangible-assets-tables
463 Statement Table [Table] Table

*

*

 acst:StatementTable
464 Legal Entity [Axis] Axis dei:LegalEntityAxis
465 Entity [Domain] Member dei:EntityDomain
466 Statement Line Items [Line Items] LineItems acst:StatementLineItems
467 Disclosure of detailed information about intangible assets [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
468 037 - Disclosure - Note 10 - Trade and Other Payables (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-10-trade-and-other-payables-tables
469 Statement Table [Table] Table

*

*

 acst:StatementTable
470 Legal Entity [Axis] Axis dei:LegalEntityAxis
471 Entity [Domain] Member dei:EntityDomain
472 Statement Line Items [Line Items] LineItems acst:StatementLineItems
473 Disclosure of detailed information about trade and other payables [text block] Concept (Text Block (HTML)) For Period acst:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock
474 038 - Disclosure - Note 11 - Derivative Warrant Liabilities (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-11-derivative-warrant-liabilities-tables
475 Statement Table [Table] Table

*

*

 acst:StatementTable
476 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
477 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
478 Derivative warrant liabilities [member] Member acst:DerivativeWarrantLiabilitiesMember
479 Legal Entity [Axis] Axis dei:LegalEntityAxis
480 Entity [Domain] Member dei:EntityDomain
481 Statement Line Items [Line Items] LineItems acst:StatementLineItems
482 Disclosure of maturity analysis for derivative financial liabilities [text block] Concept (Text Block (HTML)) For Period ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities
483 Disclosure of sensitivity analysis for actuarial assumptions [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory
484 039 - Disclosure - Note 12 - Unsecured Convertible Debentures (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-12-unsecured-convertible-debentures-tables
485 Statement Table [Table] Table

*

*

 acst:StatementTable
486 Legal Entity [Axis] Axis dei:LegalEntityAxis
487 Entity [Domain] Member dei:EntityDomain
488 Statement Line Items [Line Items] LineItems acst:StatementLineItems
489 Disclosure of detailed information about borrowings [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
490 040 - Disclosure - Note 13 - Capital and Other Components of Equity (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-13-capital-and-other-components-of-equity-tables
491 Statement Table [Table] Table

*

*

 acst:StatementTable
492 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
493 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
494 Warrants [member] Member acst:WarrantsMember
495 Legal Entity [Axis] Axis dei:LegalEntityAxis
496 Entity [Domain] Member dei:EntityDomain
497 Statement Line Items [Line Items] LineItems acst:StatementLineItems
498 Disclosure of sensitivity analysis for actuarial assumptions [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory
499 Disclosure of convertible debentures [text block] Concept (Text Block (HTML)) For Period acst:DisclosureOfConvertibleDebenturesTextBlock
500 Class of warrant or right outstanding [text block] Concept (Text Block (HTML)) For Period acst:ClassOfWarrantOrRightOutstandingTextBlock
501 041 - Disclosure - Note 14 - Personnel Expenses (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-14-personnel-expenses-tables
502 Statement Table [Table] Table

*

*

 acst:StatementTable
503 Legal Entity [Axis] Axis dei:LegalEntityAxis
504 Entity [Domain] Member dei:EntityDomain
505 Statement Line Items [Line Items] LineItems acst:StatementLineItems
506 Disclosure of components of personnel expenses [text block] Concept (Text Block (HTML)) For Period acst:DisclosureOfComponentsOfPersonnelExpensesTextBlock
507 042 - Disclosure - Note 15 - Financial Expenses (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-15-financial-expenses-tables
508 Statement Table [Table] Table

*

*

 acst:StatementTable
509 Legal Entity [Axis] Axis dei:LegalEntityAxis
510 Entity [Domain] Member dei:EntityDomain
511 Statement Line Items [Line Items] LineItems acst:StatementLineItems
512 Disclosure for components of finance income (cost) [text block] Concept (Text Block (HTML)) For Period acst:DisclosureForComponentsOfFinanceIncomeCostTextBlock
513 043 - Disclosure - Note 16 - Share-based Payments (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-16-sharebased-payments-tables
514 Statement Table [Table] Table

*

*

 acst:StatementTable
515 Legal Entity [Axis] Axis dei:LegalEntityAxis
516 Entity [Domain] Member dei:EntityDomain
517 Statement Line Items [Line Items] LineItems acst:StatementLineItems
518 Disclosure of number and weighted average exercise prices of share options [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
519 Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
520 Disclosure of range of exercise prices of outstanding share options [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory
521 044 - Disclosure - Note 18 - Supplemental Cash Flow Disclosure (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-18-supplemental-cash-flow-disclosure-tables
522 Statement Table [Table] Table

*

*

 acst:StatementTable
523 Legal Entity [Axis] Axis dei:LegalEntityAxis
524 Entity [Domain] Member dei:EntityDomain
525 Statement Line Items [Line Items] LineItems acst:StatementLineItems
526 Disclosure of changes in noncash operating items [Text Block] Concept (Text Block (HTML)) For Period acst:DisclosureOfChangesInNoncashOperatingItemsTextBlock
527 Disclosure of noncash transactions [Text Block] Concept (Text Block (HTML)) For Period acst:DisclosureOfNoncashTransactionsTextBlock
528 045 - Disclosure - Note 19 - Income Taxes (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-19-income-taxes-tables
529 Statement Table [Table] Table

*

*

 acst:StatementTable
530 Legal Entity [Axis] Axis dei:LegalEntityAxis
531 Entity [Domain] Member dei:EntityDomain
532 Statement Line Items [Line Items] LineItems acst:StatementLineItems
533 Changes in deferred tax liability (asset) [Text Block] Concept (Text Block (HTML)) For Period acst:ChangesInDeferredTaxLiabilityAssetTextBlock
534 Reconciliation of accounting profit multiplied by applicable tax rates [Text Block] Concept (Text Block (HTML)) For Period acst:ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock
535 Disclosure of unrecognized deferred tax assets [text block] Concept (Text Block (HTML)) For Period acst:DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock
536 Tax attributes and temporary differences, which are available to reduce future years’ taxable income [Text Block] Concept (Text Block (HTML)) For Period acst:TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock
537 046 - Disclosure - Note 20 - Financial Instruments (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-20-financial-instruments-tables
538 Statement Table [Table] Table

*

*

 acst:StatementTable
539 Legal Entity [Axis] Axis dei:LegalEntityAxis
540 Entity [Domain] Member dei:EntityDomain
541 Statement Line Items [Line Items] LineItems acst:StatementLineItems
542 Disclosure of effect of changes in foreign exchange rates [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory
543 Disclosure of financial instruments by type of interest rate [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory
544 Disclosure of financial liabilities [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory
545 047 - Disclosure - Note 23 - Capital Management (Tables) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-23-capital-management-tables
546 Statement Table [Table] Table

*

*

 acst:StatementTable
547 Legal Entity [Axis] Axis dei:LegalEntityAxis
548 Entity [Domain] Member dei:EntityDomain
549 Statement Line Items [Line Items] LineItems acst:StatementLineItems
550 Disclosure of cash and cash equivalents [text block] Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
551 048 - Disclosure - Note 1 - Reporting Entity (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-1-reporting-entity-details-textual
552 Statement Table [Table] Table

*

*

 acst:StatementTable
553 Legal Entity [Axis] Axis dei:LegalEntityAxis
554 Entity [Domain] Member dei:EntityDomain
555 Neptune Technologies and Bioressources Inc. [member] Member acst:NeptuneTechnologiesAndBioressourcesIncMember
556 Associates [axis] Axis ifrs-full:SignificantInvestmentsInAssociatesAxis
557 Entity's total for associates [member] Member ifrs-full:EntitysTotalForAssociatesMember
558 Acasti Pharma Inc. [member] Member acst:AcastiPharmaIncMember
559 Statement Line Items [Line Items] LineItems acst:StatementLineItems
560 Proportion of ownership interest in associate Concept (Percent) For Period ifrs-full:ProportionOfOwnershipInterestInAssociate
561 049 - Disclosure - Note 2 - Basis of Preparation (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-2-basis-of-preparation-details-textual
562 Statement Table [Table] Table

*

*

 acst:StatementTable
563 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
564 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
565 Major ordinary share transactions [member] Member ifrs-full:MajorOrdinaryShareTransactionsMember
566 Legal Entity [Axis] Axis dei:LegalEntityAxis
567 Entity [Domain] Member dei:EntityDomain
568 Statement Line Items [Line Items] LineItems acst:StatementLineItems
569 Total current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
570 Total cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
571 Current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
572 Increase in current assets from a public financing Concept (Monetary) For Period Debit acst:IncreaseInCurrentAssetsFromAPublicFinancing
573 050 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-3-significant-accounting-policies-details-textual
574 Statement Table [Table] Table

*

*

 acst:StatementTable
575 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
576 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
577 FRANCE Member country:FR
578 Legal Entity [Axis] Axis dei:LegalEntityAxis
579 Entity [Domain] Member dei:EntityDomain
580 Statement Line Items [Line Items] LineItems acst:StatementLineItems
581 Assets at end of period Concept (Monetary) As Of Debit ifrs-full:Assets
582 051 - Disclosure - Note 3 - Significant Accounting Policies - Estimated Useful Lives and Rates (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details
583 Statement Table [Table] Table

*

*

 acst:StatementTable
584 Range [axis] Axis ifrs-full:RangeAxis
585 Ranges [member] Member ifrs-full:RangesMember
586 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
587 Top of range [member] Member ifrs-full:TopOfRangeMember
588 Classes of property, plant and equipment [axis] Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
589 Property, plant and equipment [member] Member ifrs-full:PropertyPlantAndEquipmentMember
590 Furniture and office equipment [member] Member acst:FurnitureAndOfficeEquipmentMember
591 Computer equipment [member] Member ifrs-full:ComputerEquipmentMember
592 Laboratory equipment [member] Member acst:LaboratoryEquipmentMember
593 Production equipment [member] Member acst:ProductionEquipmentMember
594 Classes of intangible assets and goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis
595 Intangible assets and goodwill [member] Member ifrs-full:IntangibleAssetsAndGoodwillMember
596 Patents [member] Member acst:PatentsMember
597 Licences [member] Member ifrs-full:LicencesMember
598 Legal Entity [Axis] Axis dei:LegalEntityAxis
599 Entity [Domain] Member dei:EntityDomain
600 Statement Line Items [Line Items] LineItems acst:StatementLineItems
601 Furniture and office equipment Concept (Percent) For Period acst:DepreciationPercentage
602 Production equipment (in years) (Year) Concept (xbrli:durationItemType) For Period acst:UsefulLifeOfAssets
603 Useful life, intangible assets (Year) Concept (xbrli:durationItemType) For Period acst:IntangibleAssetsUsefulLife
604 052 - Disclosure - Note 4 - Receivables - Schedule of Receivables (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-4-receivables-schedule-of-receivables-details
605 Statement Table [Table] Table

*

*

 acst:StatementTable
606 Legal Entity [Axis] Axis dei:LegalEntityAxis
607 Entity [Domain] Member dei:EntityDomain
608 Statement Line Items [Line Items] LineItems acst:StatementLineItems
609 Sales tax receivables Concept (Monetary) As Of Debit ifrs-full:CurrentValueAddedTaxReceivables
610 Government assistance and tax credits receivable Concept (Monetary) As Of Debit acst:GovernmentAssistanceAndTaxCreditsReceivable
611 Other receivables Concept (Monetary) As Of Debit ifrs-full:OtherCurrentReceivables
612 Total receivables Concept (Monetary) As Of Debit ifrs-full:TradeAndOtherCurrentReceivables
613 053 - Disclosure - Note 5 - Other Assets (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-5-other-assets-details-textual
614 Statement Table [Table] Table

*

*

 acst:StatementTable
615 Classes of assets [axis] Axis ifrs-full:ClassesOfAssetsAxis
616 Assets [member] Member ifrs-full:ClassesOfAssetsMember
617 Krill oil [member] Member acst:KrillOilMember
618 Legal Entity [Axis] Axis dei:LegalEntityAxis
619 Entity [Domain] Member dei:EntityDomain
620 Statement Line Items [Line Items] LineItems acst:StatementLineItems
621 Purchase of other assets Concept (Monetary) For Period Credit acst:PurchaseOfOtherAssets
622 Research and development expense Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
623 Other assets damaged and received credit Concept (Monetary) For Period Debit acst:OtherAssetsDamagedAndReceivedCredit
624 Other assets Concept (Monetary) As Of Debit ifrs-full:OtherAssets
625 Other current assets Concept (Monetary) As Of Debit ifrs-full:OtherCurrentAssets
626 054 - Disclosure - Note 6 - Related Parties (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-6-related-parties-details-textual
627 Statement Table [Table] Table

*

*

 acst:StatementTable
628 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
629 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
630 Neptune [member] Member acst:NeptuneMember
631 Parent [member] Member ifrs-full:ParentMember
632 Key management personnel of entity or parent [member] Member ifrs-full:KeyManagementPersonnelOfEntityOrParentMember
633 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
634 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
635 Biodroga Nutraceuticals Inc. [member] Member acst:BiodrogaNutraceuticalsIncMember
636 Maturity [axis] Axis ifrs-full:MaturityAxis
637 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
638 Not later than six months [member] Member acst:NotLaterThanSixMonthsMember
639 Later than six months [member] Member ifrs-full:LaterThanSixMonthsMember
640 Range [axis] Axis ifrs-full:RangeAxis
641 Ranges [member] Member ifrs-full:RangesMember
642 Top of range [member] Member ifrs-full:TopOfRangeMember
643 Legal Entity [Axis] Axis dei:LegalEntityAxis
644 Entity [Domain] Member dei:EntityDomain
645 Statement Line Items [Line Items] LineItems acst:StatementLineItems
646 Current payables to related parties Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
647 Contingent liabilities recognised in business combination at end of period Concept (Monetary) As Of Credit ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
648 Borrowings, interest rate Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
649 Interest income (expense) Concept (Monetary) For Period Credit ifrs-full:InterestRevenueExpense
650 Proportion of voting rights held by an associate Concept (Percent) For Period acst:ProportionOfVotingRightsHeldByAnAssociate
651 055 - Disclosure - Note 6 - Related Parties - Administrative and Research and Development Expenses (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-6-related-parties-administrative-and-research-and-development-expenses-details
652 Statement Table [Table] Table

*

*

 acst:StatementTable
653 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
654 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
655 Neptune [member] Member acst:NeptuneMember
656 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
657 Products and services [member] Member ifrs-full:ProductsAndServicesMember
658 Supplies and incremental costs [member] Member acst:SuppliesAndIncrementalCostsMember
659 Shared service agreement [member] Member acst:SharedServiceAgreementMember
660 Legal Entity [Axis] Axis dei:LegalEntityAxis
661 Entity [Domain] Member dei:EntityDomain
662 Statement Line Items [Line Items] LineItems acst:StatementLineItems
663 Research and development expenses Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
664 General and administrative expenses Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
665 Total related parties expenses Concept (Monetary) For Period Debit acst:ResearchDevelopmentGeneralAndAdministrationExpense
666 056 - Disclosure - Note 6 - Related Parties - Key Management Personnel Compensation (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-6-related-parties-key-management-personnel-compensation-details
667 Statement Table [Table] Table

*

*

 acst:StatementTable
668 Legal Entity [Axis] Axis dei:LegalEntityAxis
669 Entity [Domain] Member dei:EntityDomain
670 Statement Line Items [Line Items] LineItems acst:StatementLineItems
671 Compensation Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
672 Severance Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
673 Share-based compensation costs Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
674 Total key management personnel compensation Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensation
675 057 - Disclosure - Note 7 - Government Assistance - Government Grants and Investment Tax Credits (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-7-government-assistance-government-grants-and-investment-tax-credits-details
676 Statement Table [Table] Table

*

*

 acst:StatementTable
677 Legal Entity [Axis] Axis dei:LegalEntityAxis
678 Entity [Domain] Member dei:EntityDomain
679 Statement Line Items [Line Items] LineItems acst:StatementLineItems
680 Investment tax credit Concept (Monetary) For Period Credit acst:InvestmentTaxCredit
681 Government grant Concept (Monetary) For Period Credit ifrs-full:RevenueFromGovernmentGrants
682 Total government assistance Concept (Monetary) For Period Credit acst:GovernmentGrantsAndInvestmentTaxCredits
683 058 - Disclosure - Note 7 - Government Assistance - Unrecognized Federal Tax Credits (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-7-government-assistance-unrecognized-federal-tax-credits-details
684 Statement Table [Table] Table

*

*

 acst:StatementTable
685 Maturity [axis] Axis ifrs-full:MaturityAxis
686 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
687 Later than eleven years and not later than twelve years [member] Member acst:LaterThanElevenYearsAndNotLaterThanTwelveYearsMember
688 Later than twelve years and not later than thirteen years [member] Member acst:LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember
689 Later than thirteen years and not later than fourteen years [member] Member acst:LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember
690 Later than fourteen years and not later than fifteen years [member] Member acst:LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember
691 Later than fifteen years and not later than sixteen years [member] Member acst:LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember
692 Later than sixteen years and not later than seventeen years [member] Member acst:LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember
693 Later than seventeen years and not later than eighteen years [member] Member acst:LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember
694 Later than eighteen years and not later than nineteen years [member] Member acst:LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember
695 Later than nineteen years and not later than twenty years [member] Member acst:LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember
696 Later than twenty years and not later than twenty-one years [member] Member acst:LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember
697 Legal Entity [Axis] Axis dei:LegalEntityAxis
698 Entity [Domain] Member dei:EntityDomain
699 Statement Line Items [Line Items] LineItems acst:StatementLineItems
700 Unrecognized federal tax credits may be used to reduce future income tax and expire Concept (Monetary) As Of ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
701 059 - Disclosure - Note 8 - Equipment (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-8-equipment-details-textual
702 Statement Table [Table] Table

*

*

 acst:StatementTable
703 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
704 Carrying amount [member] Member ifrs-full:CarryingAmountMember
705 Gross carrying amount [member] Member ifrs-full:GrossCarryingAmountMember
706 Legal Entity [Axis] Axis dei:LegalEntityAxis
707 Entity [Domain] Member dei:EntityDomain
708 Statement Line Items [Line Items] LineItems acst:StatementLineItems
709 Increase (decrease) through transfers, property, plant and equipment Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
710 060 - Disclosure - Note 8 - Equipment - Components of Equipment (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-8-equipment-components-of-equipment-details
711 Statement Table [Table] Table

*

*

 acst:StatementTable
712 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
713 Carrying amount [member] Member ifrs-full:CarryingAmountMember
714 Gross carrying amount [member] Member ifrs-full:GrossCarryingAmountMember
715 Accumulated depreciation, amortisation and impairment [member] Member ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember
716 Classes of property, plant and equipment [axis] Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
717 Property, plant and equipment [member] Member ifrs-full:PropertyPlantAndEquipmentMember
718 Furniture and office equipment [member] Member acst:FurnitureAndOfficeEquipmentMember
719 Computer equipment [member] Member ifrs-full:ComputerEquipmentMember
720 Laboratory equipment [member] Member acst:LaboratoryEquipmentMember
721 Production equipment [member] Member acst:ProductionEquipmentMember
722 Legal Entity [Axis] Axis dei:LegalEntityAxis
723 Entity [Domain] Member dei:EntityDomain
724 Statement Line Items [Line Items] LineItems acst:StatementLineItems
725 Balance Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
726 Additions Concept (Monetary) For Period Debit ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
727 Balance Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
728 Depreciation for the period Concept (Monetary) For Period ifrs-full:DepreciationPropertyPlantAndEquipment
729 061 - Disclosure - Note 9 - Intangible Assets - Components of Intangible Assets (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-9-intangible-assets-components-of-intangible-assets-details
730 Statement Table [Table] Table

*

*

 acst:StatementTable
731 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
732 Carrying amount [member] Member ifrs-full:CarryingAmountMember
733 Gross carrying amount [member] Member ifrs-full:GrossCarryingAmountMember
734 Accumulated depreciation, amortisation and impairment [member] Member ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember
735 Classes of intangible assets and goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis
736 Intangible assets and goodwill [member] Member ifrs-full:IntangibleAssetsAndGoodwillMember
737 Patents [member] Member acst:PatentsMember
738 Licences [member] Member ifrs-full:LicencesMember
739 Legal Entity [Axis] Axis dei:LegalEntityAxis
740 Entity [Domain] Member dei:EntityDomain
741 Statement Line Items [Line Items] LineItems acst:StatementLineItems
742 Balance Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsAndGoodwill
743 Additions Concept (Monetary) For Period Debit ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
744 Balance Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsAndGoodwill
745 Amortization for the period Concept (Monetary) For Period ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
746 Impairment loss Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
747 062 - Disclosure - Note 10 - Trade and Other Payables - Components of Trade and Other Payables (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-10-trade-and-other-payables-components-of-trade-and-other-payables-details
748 Statement Table [Table] Table

*

*

 acst:StatementTable
749 Legal Entity [Axis] Axis dei:LegalEntityAxis
750 Entity [Domain] Member dei:EntityDomain
751 Statement Line Items [Line Items] LineItems acst:StatementLineItems
752 Trade payables Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
753 Accrued liabilities and other payables Concept (Monetary) As Of Credit ifrs-full:AccrualsClassifiedAsCurrent
754 Employee salaries and benefits payable Concept (Monetary) As Of Credit ifrs-full:ShorttermEmployeeBenefitsAccruals
755 Current payables to related parties Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
756 Total trade and other payables Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
757 063 - Disclosure - Note 11 - Derivative Warrant Liabilities (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-11-derivative-warrant-liabilities-details-textual
758 Statement Table [Table] Table

*

*

 acst:StatementTable
759 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
760 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
761 Warrant liabilities issued December 27, 2017 [member] Member acst:WarrantLiabilitiesIssuedDecember272017Member
762 Warrant liabilities issued December 3, 2013 [member] Member acst:WarrantLiabilitiesIssuedDecember32013Member
763 Legal Entity [Axis] Axis dei:LegalEntityAxis
764 Entity [Domain] Member dei:EntityDomain
765 Statement Line Items [Line Items] LineItems acst:StatementLineItems
766 Fair value per shares issuable warrants Concept (Share) As Of acst:FairValuePerSharesIssuableWarrants
767 Number of required warrants to be exercised to obtain one common share Concept (Shares) As Of acst:NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare
768 064 - Disclosure - Note 11 - Derivative Warrant Liabilities - Reconciliation (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-11-derivative-warrant-liabilities-reconciliation-details
769 Statement Table [Table] Table

*

*

 acst:StatementTable
770 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
771 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
772 Warrant liabilities issued December 27, 2017 [member] Member acst:WarrantLiabilitiesIssuedDecember272017Member
773 Warrant liabilities issued December 3, 2013 [member] Member acst:WarrantLiabilitiesIssuedDecember32013Member
774 Legal Entity [Axis] Axis dei:LegalEntityAxis
775 Entity [Domain] Member dei:EntityDomain
776 Statement Line Items [Line Items] LineItems acst:StatementLineItems
777 Balance – beginning of period Concept (Monetary) As Of Credit ifrs-full:CurrentDerivativeFinancialLiabilities
778 Issued during period (note 13b) Concept (Monetary) For Period Credit acst:DerivativeFinancialLiabilitiesIssued
779 Change in fair value of derivative warrant liabilities Concept (Monetary) For Period Credit ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability
780 Balance – end of period Concept (Monetary) As Of Credit ifrs-full:CurrentDerivativeFinancialLiabilities
781 065 - Disclosure - Note 11 - Derivative Warrant Liabilities - Assumptions (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-11-derivative-warrant-liabilities-assumptions-details
782 Statement Table [Table] Table

*

*

 acst:StatementTable
783 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
784 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
785 Warrant liabilities issued December 27, 2017 [member] Member acst:WarrantLiabilitiesIssuedDecember272017Member
786 Warrant liabilities issued December 3, 2013 [member] Member acst:WarrantLiabilitiesIssuedDecember32013Member
787 Legal Entity [Axis] Axis dei:LegalEntityAxis
788 Entity [Domain] Member dei:EntityDomain
789 Statement Line Items [Line Items] LineItems acst:StatementLineItems
790 Exercise price Concept (Monetary) For Period acst:ExercisePriceWarrantsIssued
791 Share price Concept (Monetary) For Period acst:WeightedAverageSharePriceWarrantsIssued
792 Dividend Concept (Monetary) For Period acst:ExpectedDividendWarrantsIssued
793 Risk-free interest Concept (Percent) For Period acst:RiskFreeInterestRateWarrantsIssued
794 Estimated life (in years) Concept (xbrli:durationItemType) For Period acst:WarrantLifeWarrantsIssued
795 Expected volatility Concept (Percent) For Period acst:ExpectedVolatilityWarrantsIssued
796 066 - Disclosure - Note 12 - Unsecured Convertible Debentures (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-12-unsecured-convertible-debentures-details-textual
797 Statement Table [Table] Table

*

*

 acst:StatementTable
798 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
799 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
800 Unsecured convertible debentures [member] Member acst:UnsecuredConvertibleDebenturesMember
801 Legal Entity [Axis] Axis dei:LegalEntityAxis
802 Entity [Domain] Member dei:EntityDomain
803 Statement Line Items [Line Items] LineItems acst:StatementLineItems
804 Notional amount Concept (Monetary) As Of ifrs-full:NotionalAmount
805 Maximum number of common shares issuable from contingent warrants Concept (Shares) As Of acst:MaximumNumberOfCommonSharesIssuableFromContingentWarrants
806 Borrowings, convertible, conversion price Concept (Share) As Of acst:BorrowingsConvertibleConversionPrice
807 Warrants exercisable price per share after borrowings conversion Concept (Share) As Of acst:WarrantsExercisablePricePerShareAfterBorrowingsConversion
808 Borrowings, discount of borrowing principal amount Concept (Percent) As Of acst:BorrowingsDiscountOfBorrowingPrincipalAmount
809 Proceeds from borrowings, classified as financing activities Concept (Monetary) For Period Debit ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
810 Borrowings, accelerated conversion feature, minimum time after issuance date Concept (xbrli:durationItemType) For Period acst:BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate
811 Borrowings, accelerated conversion feature, weighted average share price minimum Concept (Share) As Of acst:BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum
812 Borrowings, convertible, threshold consecutive trading days Concept (xbrli:durationItemType) For Period acst:BorrowingsConvertibleThresholdConsecutiveTradingDays
813 Borrowings, interest rate Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
814 Borrowings, convertible, equity issued, floor price Concept (Share) As Of acst:BorrowingsConvertibleEquityIssuedFloorPrice
815 Discount rate applied to cash flow projections Concept (Percent) As Of ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
816 067 - Disclosure - Note 12 - Unsecured Convertible Debentures - Liability and Equity Component Portions (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-12-unsecured-convertible-debentures-liability-and-equity-component-portions-details
817 Statement Table [Table] Table

*

*

 acst:StatementTable
818 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
819 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
820 Liability portion of unsecured convertible debentures [member] Member acst:LiabilityPortionOfUnsecuredConvertibleDebenturesMember
821 Equity component of unsecured convertible debentures [member] Member acst:EquityComponentOfUnsecuredConvertibleDebenturesMember
822 Unsecured convertible debentures [member] Member acst:UnsecuredConvertibleDebenturesMember
823 Legal Entity [Axis] Axis dei:LegalEntityAxis
824 Entity [Domain] Member dei:EntityDomain
825 Statement Line Items [Line Items] LineItems acst:StatementLineItems
826 Balance Concept (Monetary) As Of Credit ifrs-full:Borrowings
827 Transaction costs and debt discount Concept (Monetary) For Period ifrs-full:BorrowingCostsIncurred
828 Deferred income tax expense (note 18) Concept (Monetary) For Period Debit ifrs-full:DeferredTaxExpenseIncome
829 Effective interest Concept (Monetary) For Period Debit ifrs-full:InterestExpenseOnBorrowings
830 Interest payable Concept (Monetary) For Period ifrs-full:InterestCostsIncurred
831 Balance Concept (Monetary) As Of Credit ifrs-full:Borrowings
832 068 - Disclosure - Note 13 - Capital and Other Components of Equity (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-13-capital-and-other-components-of-equity-details-textual
833 Statement Table [Table] Table

*

*

 acst:StatementTable
834 Classes of share capital [axis] Axis ifrs-full:ClassesOfShareCapitalAxis
835 Share capital [member] Member ifrs-full:ClassesOfShareCapitalMember
836 Class B shares [Member] Member acst:ClassBSharesMember
837 Class C shares [Member] Member acst:ClassCSharesMember
838 Class D and E shares [Member] Member acst:ClassDAndESharesMember
839 Class A shares [member] Member acst:ClassASharesMember
840 Range [axis] Axis ifrs-full:RangeAxis
841 Ranges [member] Member ifrs-full:RangesMember
842 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
843 Top of range [member] Member ifrs-full:TopOfRangeMember
844 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
845 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
846 Class A shares [member] Member acst:ClassASharesMember
847 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
848 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
849 Warrant liabilities issued December 27, 2017 [member] Member acst:WarrantLiabilitiesIssuedDecember272017Member
850 Derivative warrant liabilities [member] Member acst:DerivativeWarrantLiabilitiesMember
851 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
852 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
853 Underwriter [member] Member acst:UnderwriterMember
854 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
855 Counterparties [member] Member ifrs-full:CounterpartiesMember
856 Underwriter [member] Member acst:UnderwriterMember
857 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
858 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
859 Exercised portion of a over-allotment option [member] Member acst:ExercisedPortionOfAOverallotmentOptionMember
860 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
861 Equity [member] Member ifrs-full:EquityMember
862 Additional paid-in capital [member] Member ifrs-full:AdditionalPaidinCapitalMember
863 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
864 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
865 Public offering warrants 2017 related to liability [member] Member acst:PublicOfferingWarrants2017RelatedToLiabilityMember
866 Series 8 December 2013 Public offering warrants related to liability [member] Member acst:Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember
867 Series 2017-BW Broker warrants related to equity [member] Member acst:Series2017BWBrokerWarrantsRelatedToEquityMember
868 Public offering warrants February 2017, equity portion [member] Member acst:PublicOfferingWarrantsFebruary2017EquityPortionMember
869 Series December 2017 US Broker warrants, equity portion [member] Member acst:SeriesDecember2017UsBrokerWarrantsEquityPortionMember
870 The 2017 Unsecured convertible debenture conversion option and contingent warrant related to equity [member] Member acst:The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember
871 Series 9 Private Placement warrants 2013 related to equity [member] Member acst:Series9PrivatePlacementWarrants2013RelatedToEquityMember
872 Legal Entity [Axis] Axis dei:LegalEntityAxis
873 Entity [Domain] Member dei:EntityDomain
874 Statement Line Items [Line Items] LineItems acst:StatementLineItems
875 Non-cumulative dividend rate Concept (Percent) As Of acst:NonCumulativeDividendRate
876 Conversion ratio Concept (Pure) For Period acst:ConversionRatio
877 Redeemable price per share Concept (Share) As Of acst:RedeemablePricePerShare
878 Number of shares outstanding at end of period Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
879 Number of units issued during period Concept (Shares) For Period acst:NumberOfUnitsIssuedDuringPeriod
880 Unit issued, price per unit Concept (Share) As Of acst:UnitIssuedPricePerUnit
881 Proceeds from issuing units Concept (Monetary) For Period Debit acst:ProceedsFromIssuingUnits
882 Warrants exercised, equity shares issued, amount Concept (Monetary) For Period Credit acst:WarrantsExercisedEquitySharesIssuedAmount
883 Number of shares called by warrants Concept (Shares) As Of acst:NumberOfSharesCalledByWarrants
884 Exercise price, warrants issued Concept (Monetary) For Period acst:ExercisePriceWarrantsIssued
885 Proceeds from exercise of warrants Concept (Monetary) For Period Debit acst:ProceedsFromExerciseOfWarrants
886 Total financial liabilities at fair value through profit or loss Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
887 Warrant costs Concept (Monetary) For Period Debit acst:WarrantCosts
888 Fair value per shares issuable warrants Concept (Share) As Of acst:FairValuePerSharesIssuableWarrants
889 Unit, shares of class A share Concept (Shares) As Of acst:UnitSharesOfClassAShare
890 Unit, shares of class A share purchase warrant Concept (Shares) As Of acst:UnitSharesOfClassASharePurchaseWarrant
891 Number of shares called by each warrant Concept (Shares) As Of acst:NumberOfSharesCalledByEachWarrant
892 Unit issuance costs Concept (Monetary) For Period Debit acst:UnitIssuanceCosts
893 Warrants and rights outstanding Concept (Monetary) As Of Credit acst:WarrantsAndRightsOutstanding
894 Weighted average share price Concept (Monetary) For Period ifrs-full:WeightedAverageSharePrice
895 Increase (decrease) from equity settled non-employee share-based payment, shares Concept (Shares) For Period acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares
896 Share issued, price per share Concept (Share) As Of acst:ShareIssuedPricePerShare
897 Increase (decrease) from equity settled non-employee share-based payment Concept (Monetary) For Period Credit acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment
898 Share-based payment costs allocated to share capital Concept (Monetary) For Period Credit acst:ShareBasedPaymentCostsAllocatedToShareCapital
899 Share-based payment costs allocated to debt Concept (Monetary) For Period Credit acst:ShareBasedPaymentCostsAllocatedToDebt
900 Exercise price for 10 warrants Concept (Share) As Of acst:ExercisePriceFor10Warrants
901 Warrants exercised, equity shares issued Concept (Shares) For Period acst:WarrantsExercisedEquitySharesIssued
902 Warrants expired Concept (Shares) For Period acst:WarrantsExpired
903 Deferred tax expense (income) Concept (Monetary) For Period Debit ifrs-full:DeferredTaxExpenseIncome
904 Total number of shares issued Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
905 069 - Disclosure - Note 13 - Capital and Other Components of Equity - Assumptions (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-13-capital-and-other-components-of-equity-assumptions-details
906 Statement Table [Table] Table

*

*

 acst:StatementTable
907 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
908 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
909 Public offering warrants in 2017 [member] Member acst:PublicOfferingWarrantsIn2017Member
910 Broker warrants [member] Member acst:BrokerWarrantsMember
911 Legal Entity [Axis] Axis dei:LegalEntityAxis
912 Entity [Domain] Member dei:EntityDomain
913 Statement Line Items [Line Items] LineItems acst:StatementLineItems
914 Exercise price, warrants issued Concept (Monetary) For Period acst:ExercisePriceWarrantsIssued
915 Share price Concept (Monetary) For Period acst:WeightedAverageSharePriceWarrantsIssued
916 Risk-free interest Concept (Percent) For Period acst:RiskFreeInterestRateWarrantsIssued
917 Estimated life (in years) (Year) Concept (xbrli:durationItemType) For Period acst:WarrantLifeWarrantsIssued
918 Expected volatility Concept (Percent) For Period acst:ExpectedVolatilityWarrantsIssued
919 Dividend Concept (Monetary) For Period acst:ExpectedDividendWarrantsGranted
920 070 - Disclosure - Note 13 - Capital and Other Components of Equity - Unsecured Convertible Debentures (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-13-capital-and-other-components-of-equity-unsecured-convertible-debentures-details
921 Statement Table [Table] Table

*

*

 acst:StatementTable
922 Legal Entity [Axis] Axis dei:LegalEntityAxis
923 Entity [Domain] Member dei:EntityDomain
924 Statement Line Items [Line Items] LineItems acst:StatementLineItems
925 Number of shares (in shares) Concept (Shares) For Period acst:ConversionOfConvertibleInstrumentsEquitySharesIssued
926 Amount Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
927 071 - Disclosure - Note 13 - Capital and Other Components of Equity - Warrants Outstanding (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-13-capital-and-other-components-of-equity-warrants-outstanding-details
928 Statement Table [Table] Table

*

*

 acst:StatementTable
929 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
930 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
931 Series December 2017 US Broker warrants, liability portion [member] Member acst:SeriesDecember2017UsBrokerWarrantsLiabilityPortionMember
932 Series 8 December 2013 Public offering warrants related to liability [member] Member acst:Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember
933 Warrants relating to liabilities [member] Member acst:WarrantsRelatingToLiabilitiesMember
934 Series December 2017 US Broker warrants, equity portion [member] Member acst:SeriesDecember2017UsBrokerWarrantsEquityPortionMember
935 Series 2017-BW Broker warrants related to equity [member] Member acst:Series2017BWBrokerWarrantsRelatedToEquityMember
936 Public offering warrants February 2017, equity portion [member] Member acst:PublicOfferingWarrantsFebruary2017EquityPortionMember
937 The 2017 Unsecured convertible debenture conversion option and contingent warrant related to equity [member] Member acst:The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember
938 Series 9 Private Placement warrants 2013 related to equity [member] Member acst:Series9PrivatePlacementWarrants2013RelatedToEquityMember
939 Warrants related to equity [member] Member acst:WarrantsRelatedToEquityMember
940 Legal Entity [Axis] Axis dei:LegalEntityAxis
941 Entity [Domain] Member dei:EntityDomain
942 Statement Line Items [Line Items] LineItems acst:StatementLineItems
943 Warrants (in shares) Concept (Shares) As Of acst:ClassOfWarrantOrRightOutstanding
944 Warrants and rights outstanding Concept (Monetary) As Of Credit acst:WarrantsAndRightsOutstanding
945 072 - Disclosure - Note 14 - Personnel Expenses - Components of Personnel Expenses (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-14-personnel-expenses-components-of-personnel-expenses-details
946 Statement Table [Table] Table

*

*

 acst:StatementTable
947 Legal Entity [Axis] Axis dei:LegalEntityAxis
948 Entity [Domain] Member dei:EntityDomain
949 Statement Line Items [Line Items] LineItems acst:StatementLineItems
950 Salaries and other short-term employee benefits Concept (Monetary) For Period Debit ifrs-full:ShorttermEmployeeBenefitsExpense
951 Share-based compensation costs Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
952 Severance Concept (Monetary) For Period Debit ifrs-full:TerminationBenefitsExpense
953 Total personnel expenses Concept (Monetary) For Period Debit ifrs-full:EmployeeBenefitsExpense
954 073 - Disclosure - Note 15 - Financial Expenses - Components of Finance Income (Expenses) (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-15-financial-expenses-components-of-finance-income-expenses-details
955 Statement Table [Table] Table

*

*

 acst:StatementTable
956 Legal Entity [Axis] Axis dei:LegalEntityAxis
957 Entity [Domain] Member dei:EntityDomain
958 Statement Line Items [Line Items] LineItems acst:StatementLineItems
959 Interest income Concept (Monetary) For Period Credit ifrs-full:RevenueFromInterest
960 Foreign exchange gain Concept (Monetary) For Period Credit ifrs-full:NetForeignExchangeGain
961 Financial income Concept (Monetary) For Period Credit ifrs-full:FinanceIncome
962 Foreign exchange loss Concept (Monetary) For Period Debit ifrs-full:NetForeignExchangeLoss
963 Interest payable on convertible debenture during the period Concept (Monetary) For Period Debit ifrs-full:InterestExpenseOnBorrowings
964 Accretion of interest on convertible debenture Concept (Monetary) For Period Debit acst:AccretionOfInterestOnConvertibleDebenture
965 Transaction costs related to derivative warrant liabilities Concept (Monetary) For Period Debit acst:WarrantTransactionCosts
966 Other charges Concept (Monetary) For Period Debit ifrs-full:OtherExpenseByNature
967 Financial expenses Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
968 Other net financial expenses Concept (Monetary) For Period Credit ifrs-full:OtherFinanceIncomeCost
969 Change in fair value of warrant liabilities Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
970 Net Financial expenses Concept (Monetary) For Period Credit ifrs-full:FinanceIncomeCost
971 074 - Disclosure - Note 16 - Share-based Payments (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-16-sharebased-payments-details-textual
972 Statement Table [Table] Table

*

*

 acst:StatementTable
973 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
974 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
975 Corporation stock option plan [member] Member acst:CorporationStockOptionPlanMember
976 Corporation equity incentive plan [member] Member acst:CorporationEquityIncentivePlanMember
977 Range [axis] Axis ifrs-full:RangeAxis
978 Ranges [member] Member ifrs-full:RangesMember
979 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
980 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
981 Counterparties [member] Member ifrs-full:CounterpartiesMember
982 Consultants [member] Member acst:ConsultantsMember
983 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
984 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
985 Related parties [member] Member ifrs-full:RelatedPartiesMember
986 Shareholders exceeding 5% issued and outstanding stock [member] Member acst:ShareholdersExceeding5IssuedAndOutstandingStockMember
987 Legal Entity [Axis] Axis dei:LegalEntityAxis
988 Entity [Domain] Member dei:EntityDomain
989 Statement Line Items [Line Items] LineItems acst:StatementLineItems
990 Maximum number of shares authorized Concept (Shares) As Of acst:MaximumNumberOfSharesAuthorized
991 Maximum number of shares authorized as percentage Concept (Percent) As Of acst:MaximumNumberOfSharesAuthorizedAsPercentage
992 Option life, share options granted Concept (Decimal) For Period ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
993 Description of vesting period, share option granted Concept (Decimal) For Period acst:DescriptionOfVestingPeriodShareOptionGranted
994 Weighted average grant date fair value options granted in share-based payment arrangement Concept (Monetary) For Period acst:WeightedAverageGrantDateFairValueOptionsGrantedInSharebasedPaymentArrangement
995 Number of share options granted in share-based payment arrangement Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
996 Number of share options exercised in share-based payment arrangement Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
997 Weighted average share price Concept (Monetary) For Period ifrs-full:WeightedAverageSharePrice
998 Expense from share-based payment transactions with employees Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
999 Number of other equity instruments outstanding in share-based payment arrangement at end of period Concept (Decimal) As Of ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
1000 075 - Disclosure - Note 16 - Share-based Payments - Option Activity (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-16-sharebased-payments-option-activity-details
1001 Statement Table [Table] Table

*

*

 acst:StatementTable
1002 Legal Entity [Axis] Axis dei:LegalEntityAxis
1003 Entity [Domain] Member dei:EntityDomain
1004 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1005 Weighted average exercise price, outstanding Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
1006 Number of options outstanding Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
1007 Weighted average exercise price, granted Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement
1008 Options, granted Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
1009 Weighted average exercise price, forfeited Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement
1010 Options, forfeited Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
1011 Weighted average exercise price, expired Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement
1012 Options, expired Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
1013 Weighted average exercise price, exercisable Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement
1014 Exercisable at end of period Concept (Decimal) As Of ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
1015 Weighted average exercise price, exercised Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement
1016 Options, exercised Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
1017 076 - Disclosure - Note 16 - Share-based Payments - Weighted Average Assumptions (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-16-sharebased-payments-weighted-average-assumptions-details
1018 Statement Table [Table] Table

*

*

 acst:StatementTable
1019 Legal Entity [Axis] Axis dei:LegalEntityAxis
1020 Entity [Domain] Member dei:EntityDomain
1021 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1022 Exercise price Concept (Monetary) For Period ifrs-full:ExercisePriceShareOptionsGranted
1023 Share price Concept (Monetary) For Period ifrs-full:WeightedAverageSharePriceShareOptionsGranted
1024 Dividend Concept (Percent) For Period ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
1025 Risk-free interest Concept (Percent) For Period ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
1026 Estimated life (in years) Concept (Decimal) For Period ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
1027 Expected volatility Concept (Percent) For Period ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
1028 077 - Disclosure - Note 16 - Share-based Payments - Outstanding and Exercisable Options (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-16-sharebased-payments-outstanding-and-exercisable-options-details
1029 Statement Table [Table] Table

*

*

 acst:StatementTable
1030 Ranges of exercise prices for outstanding share options [axis] Axis ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis
1031 Ranges of exercise prices for outstanding share options [member] Member ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember
1032 Range one of exercises prices [member] Member acst:RangeOneOfExercisesPricesMember
1033 Range two of exercises prices [member] Member acst:RangeTwoOfExercisesPricesMember
1034 Range three of exercises prices [member] Member acst:RangeThreeOfExercisesPricesMember
1035 Range four of exercises prices [member] Member acst:RangeFourOfExercisesPricesMember
1036 Range five of exercises prices [member] Member acst:RangeFiveOfExercisesPricesMember
1037 Range [axis] Axis ifrs-full:RangeAxis
1038 Ranges [member] Member ifrs-full:RangesMember
1039 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
1040 Top of range [member] Member ifrs-full:TopOfRangeMember
1041 Legal Entity [Axis] Axis dei:LegalEntityAxis
1042 Entity [Domain] Member dei:EntityDomain
1043 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1044 Exercise price Concept (Monetary) As Of ifrs-full:ExercisePriceOfOutstandingShareOptions
1045 Weighted average remaining contractual life outstanding Concept (Decimal) As Of ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions
1046 Number of options outstanding Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
1047 Weighted average exercise price exercisable Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement
1048 Number of options exercisable Concept (Decimal) As Of ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
1049 078 - Disclosure - Note 18 - Supplemental Cash Flow Disclosure - Changes in Non-cash Operating Items (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-18-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details
1050 Statement Table [Table] Table

*

*

 acst:StatementTable
1051 Legal Entity [Axis] Axis dei:LegalEntityAxis
1052 Entity [Domain] Member dei:EntityDomain
1053 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1054 Receivables Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
1055 Receivable from corporation under common control Concept (Monetary) For Period Debit acst:AdjustmentsForDecreaseIncreaseInReceivableFromCorporationUnderCommonControl
1056 Inventories Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
1057 Prepaid expenses Concept (Monetary) For Period Debit acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
1058 Other Assets Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
1059 Trade and other payables Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
1060 Total changes in working capital items Concept (Monetary) For Period Debit ifrs-full:OtherAdjustmentsForNoncashItems
1061 079 - Disclosure - Note 18 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-18-supplemental-cash-flow-disclosure-noncash-transactions-details
1062 Statement Table [Table] Table

*

*

 acst:StatementTable
1063 Legal Entity [Axis] Axis dei:LegalEntityAxis
1064 Entity [Domain] Member dei:EntityDomain
1065 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1066 Equity settled share-based payment included in equity Concept (Monetary) For Period Credit acst:EquitySettledSharebasedPaymentIncludedInEquityAndUnsecuredConvertibleDebenturesEquityPortion
1067 Issuance of broker warrants included in net proceeds from public offering Concept (Monetary) For Period Credit acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering
1068 Public offering transaction costs included in trade and other payables Concept (Monetary) For Period Credit acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables
1069 Reduction in share issue costs from reduction in trade and other payables Concept (Monetary) For Period Credit acst:ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables
1070 Private Placement transaction costs included in trade and other payables Concept (Monetary) For Period Credit acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables
1071 Equipment included in trade and other payables Concept (Monetary) For Period Credit acst:EquipmentIncludedInTradeAndOtherPayables
1072 Interest payable included in trade and other payables Concept (Monetary) For Period Credit acst:InterestPayableIncludedInTradeAndOtherPayables
1073 Issuance of shares on settlement of a liability Concept (Monetary) For Period Credit acst:IssuanceOfSharesOnSettlementOfALiability
1074 Interest receivable included in payable to Neptune corporation Concept (Monetary) For Period Credit acst:IntangibleAssetsIncludedInTradeAndOtherPayables
1075 080 - Disclosure - Note 19 - Income Taxes (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-19-income-taxes-details-textual
1076 Statement Table [Table] Table

*

*

 acst:StatementTable
1077 Legal Entity [Axis] Axis dei:LegalEntityAxis
1078 Entity [Domain] Member dei:EntityDomain
1079 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1080 Deferred tax relating to items credited (charged) directly to equity Concept (Monetary) For Period ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
1081 081 - Disclosure - Note 19 - Income Taxes - Deferred Tax (Recovery) Expense (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-19-income-taxes-deferred-tax-recovery-expense-details
1082 Statement Table [Table] Table

*

*

 acst:StatementTable
1083 Legal Entity [Axis] Axis dei:LegalEntityAxis
1084 Entity [Domain] Member dei:EntityDomain
1085 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1086 Origination and reversal of temporary differences Concept (Monetary) For Period Debit ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
1087 Change in unrecognized deductible temporary differences Concept (Monetary) For Period Credit ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense
1088 Total tax (recovery) expense Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
1089 082 - Disclosure - Note 19 - Income Taxes - Reconciliation of Effective Tax Rate (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-19-income-taxes-reconciliation-of-effective-tax-rate-details
1090 Statement Table [Table] Table

*

*

 acst:StatementTable
1091 Legal Entity [Axis] Axis dei:LegalEntityAxis
1092 Entity [Domain] Member dei:EntityDomain
1093 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1094 Loss before income taxes Concept (Monetary) For Period Credit ifrs-full:AccountingProfit
1095 Basic combined Canadian statutory income tax rate 1 Concept (Percent) For Period ifrs-full:ApplicableTaxRate
1096 Computed income tax recovery Concept (Monetary) For Period Debit ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
1097 Change in unrecognized deductible temporary differences Concept (Monetary) For Period Debit acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences
1098 Non-deductible stock-based compensation Concept (Monetary) For Period Debit acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss
1099 Non-deductible change in fair value Concept (Monetary) For Period Debit acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss
1100 Permanent differences and other Concept (Monetary) For Period Debit acst:TaxEffectOfPermanentDifferencesAndOther
1101 Change in statutory income tax rate Concept (Monetary) For Period Debit ifrs-full:TaxEffectFromChangeInTaxRate
1102 Total tax (recovery) expense Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
1103 083 - Disclosure - Note 19 - Income Taxes - Unrecognized Deferred Tax Assets (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-19-income-taxes-unrecognized-deferred-tax-assets-details
1104 Statement Table [Table] Table

*

*

 acst:StatementTable
1105 Temporary difference, unused tax losses and unused tax credits [axis] Axis ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis
1106 Temporary difference, unused tax losses and unused tax credits [member] Member ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember
1107 Unused tax losses [member] Member ifrs-full:UnusedTaxLossesMember
1108 Research and development projects [member] Member acst:ResearchAndDevelopmentProjectsMember
1109 Property, plan and equipment and intangible assets [Member] Member acst:PropertyPlanAndEquipmentAndIntangibleAssetsMember
1110 Other temporary differences [member] Member ifrs-full:OtherTemporaryDifferencesMember
1111 Tax basis of unsecured convertible debentures in excess of carrying value [Member] Member acst:TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember
1112 Legal Entity [Axis] Axis dei:LegalEntityAxis
1113 Entity [Domain] Member dei:EntityDomain
1114 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1115 Tax losses carried forward Concept (Monetary) As Of Debit ifrs-full:DeferredTaxAssets
1116 Tax basis of unsecured convertible debentures in excess of carrying value Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilities
1117 Net deferred tax assets Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilityAsset
1118 084 - Disclosure - Note 19 - Income Taxes - Tax attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-19-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details
1119 Statement Table [Table] Table

*

*

 acst:StatementTable
1120 Maturity [axis] Axis ifrs-full:MaturityAxis
1121 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
1122 2029 [Member] Member acst:TwoThousandTwentyNineMember
1123 2030 [Member] Member acst:TwoThousandThirtyMember
1124 2031 [Member] Member acst:TwoThousandThirtyOneMember
1125 2032 [Member] Member acst:TwoThousandThirtyTwoMember
1126 2033 [Member] Member acst:TwoThousandThirtyThreeMember
1127 2034 [Member] Member acst:TwoThousandThirtyFourMember
1128 2035 [Member] Member acst:TwoThousandThirtyFiveMember
1129 2036 [Member] Member acst:TwoThousandThirtySixMember
1130 2037 [Member] Member acst:TwoThouandThirtySevenMember
1131 2038 [member] Member acst:TwoThouandThirtyEightMember
1132 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1133 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1134 Country of domicile [member] Member ifrs-full:CountryOfDomicileMember
1135 Provincial [Member] Member acst:ProvincialMember
1136 Legal Entity [Axis] Axis dei:LegalEntityAxis
1137 Entity [Domain] Member dei:EntityDomain
1138 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1139 Tax losses carried forward Concept (Monetary) As Of ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
1140 Research and development expenses, without time limitation Concept (Monetary) As Of ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
1141 Other deductible temporary differences, without time limitation Concept (Monetary) As Of ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
1142 085 - Disclosure - Note 20 - Financial Instruments - Currency Risk (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-20-financial-instruments-currency-risk-details
1143 Statement Table [Table] Table

*

*

 acst:StatementTable
1144 Types of risks [axis] Axis ifrs-full:TypesOfRisksAxis
1145 Risks [member] Member ifrs-full:TypesOfRisksMember
1146 Currency risk for USD [member] Member acst:CurrencyRiskForUSDMember
1147 Currency risk for Euro [member] Member acst:CurrencyRiskForEuroMember
1148 Currency risk [member] Member ifrs-full:CurrencyRiskMember
1149 Classes of assets [axis] Axis ifrs-full:ClassesOfAssetsAxis
1150 Assets [member] Member ifrs-full:ClassesOfAssetsMember
1151 Cash and cash equivalents [member] Member acst:CashAndCashEquivalentsMember
1152 Marketable securities [member] Member acst:MarketableSecuritiesMember
1153 Receivables [member] Member acst:ReceivablesMember
1154 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
1155 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
1156 Trade and other payables [member] Member acst:TradeAndOtherPayablesMember
1157 Legal Entity [Axis] Axis dei:LegalEntityAxis
1158 Entity [Domain] Member dei:EntityDomain
1159 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1160 Foreign exchange currency exposures Concept (Monetary) As Of Credit acst:ForeignExchangeRiskCurrencyExposure
1161 Average exchange rate Concept (Decimal) For Period ifrs-full:AverageForeignExchangeRate
1162 Closing exchange rate Concept (Decimal) As Of ifrs-full:ClosingForeignExchangeRate
1163 Decrease in net loss Concept (Monetary) As Of ifrs-full:ValueAtRisk
1164 086 - Disclosure - Note 20 - Financial Instruments - Interest Rate Risk (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-20-financial-instruments-interest-rate-risk-details
1165 Statement Table [Table] Table

*

*

 acst:StatementTable
1166 Classes of assets [axis] Axis ifrs-full:ClassesOfAssetsAxis
1167 Assets [member] Member ifrs-full:ClassesOfAssetsMember
1168 Cash and cash equivalents [member] Member acst:CashAndCashEquivalentsMember
1169 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
1170 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
1171 Unsecured convertible debentures [member] Member acst:UnsecuredConvertibleDebenturesMember
1172 Legal Entity [Axis] Axis dei:LegalEntityAxis
1173 Entity [Domain] Member dei:EntityDomain
1174 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1175 Cash and cash equivalents Concept (Text/String) For Period acst:FinancialInstrumentsDescriptionOfInterestRateRisk
1176 087 - Disclosure - Note 20 - Financial Instruments - Financial Liabilities (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-20-financial-instruments-financial-liabilities-details
1177 Statement Table [Table] Table

*

*

 acst:StatementTable
1178 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
1179 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
1180 Trade and other payables [member] Member acst:TradeAndOtherPayablesMember
1181 Unsecured convertible debentures [member] Member acst:UnsecuredConvertibleDebenturesMember
1182 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
1183 Carrying amount [member] Member ifrs-full:CarryingAmountMember
1184 Gross carrying amount [member] Member ifrs-full:GrossCarryingAmountMember
1185 Maturity [axis] Axis ifrs-full:MaturityAxis
1186 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
1187 Not later than one year [member] Member ifrs-full:NotLaterThanOneYearMember
1188 Later than one year and not later than three years [member] Member ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember
1189 Legal Entity [Axis] Axis dei:LegalEntityAxis
1190 Entity [Domain] Member dei:EntityDomain
1191 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1192 Financial liabilities Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilities
1193 088 - Disclosure - Note 21 - Commitments and Contingencies (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-21-commitments-and-contingencies-details-textual
1194 Statement Table [Table] Table

*

*

 acst:StatementTable
1195 Classes of contingent liabilities [axis] Axis ifrs-full:ClassesOfContingentLiabilitiesAxis
1196 Contingent liabilities [member] Member ifrs-full:ContingentLiabilitiesMember
1197 Research and development projects [member] Member acst:ResearchAndDevelopmentProjectsMember
1198 Former CEO [member] Member acst:FormerCEOMember
1199 Arrangements involving legal form of lease [axis] Axis ifrs-full:ArrangementsInvolvingLegalFormOfLeaseAxis
1200 Arrangements involving legal form of lease [member] Member ifrs-full:ArrangementsInvolvingLegalFormOfLeaseMember
1201 Lease for laboratory facility located in Sherbrooke, Québec [member] Member acst:LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember
1202 Maturity [axis] Axis ifrs-full:MaturityAxis
1203 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
1204 Not later than one year [member] Member ifrs-full:NotLaterThanOneYearMember
1205 Later than one year and not later than two years [member] Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
1206 Legal Entity [Axis] Axis dei:LegalEntityAxis
1207 Entity [Domain] Member dei:EntityDomain
1208 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1209 Estimated financial effect of contingent liabilities Concept (Monetary) As Of ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
1210 Minimum lease payments payable under non-cancellable operating lease Concept (Monetary) As Of Credit ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease
1211 Description of life and other significant terms of arrangement involving legal form of lease Concept (Text/String) For Period ifrs-full:DescriptionOfLifeAndOtherSignificantTermsOfArrangementInvolvingLegalFormOfLease
1212 089 - Disclosure - Note 22 - Determination of Fair Values (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-22-determination-of-fair-values-details-textual
1213 Statement Table [Table] Table

*

*

 acst:StatementTable
1214 Legal Entity [Axis] Axis dei:LegalEntityAxis
1215 Entity [Domain] Member dei:EntityDomain
1216 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1217 Significant unobservable inputs, increase in five percent of volatility would result in a loss Concept (Monetary) For Period Debit acst:SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss
1218 Significant unobservable inputs, increase in five percent of volatility would result in a gain Concept (Monetary) For Period Credit acst:SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain
1219 Significant unobservable inputs, five percent strengthen of foreign currency would result in a loss Concept (Monetary) For Period Debit acst:SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss
1220 090 - Disclosure - Note 23 - Capital Management (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-23-capital-management-details-textual
1221 Statement Table [Table] Table

*

*

 acst:StatementTable
1222 Range [axis] Axis ifrs-full:RangeAxis
1223 Ranges [member] Member ifrs-full:RangesMember
1224 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
1225 Top of range [member] Member ifrs-full:TopOfRangeMember
1226 Maturity [axis] Axis ifrs-full:MaturityAxis
1227 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
1228 Matures on April 11, 2017 [member] Member acst:MaturesOnApril112017Member
1229 Matures on April 25, 2017 [member] Member acst:MaturesOnApril252017Member
1230 Matures on March 12, 2017 [member] Member acst:MaturesOnMarch122017Member
1231 Matures on March 28, 2017 [member] Member acst:MaturesOnMarch282017Member
1232 Legal Entity [Axis] Axis dei:LegalEntityAxis
1233 Entity [Domain] Member dei:EntityDomain
1234 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1235 Short-term deposits, classified as cash equivalents Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
1236 Commercial paper, classified as cash equivalents Concept (Monetary) As Of Debit acst:CommercialPaperClassifiedAsCashEquivalents
1237 Promissory note receivable, classified as cash equivalents Concept (Monetary) As Of Debit acst:PromissoryNoteReceivableClassifiedAsCashEquivalents
1238 Borrowings, interest rate Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
1239 Long-term deposits Concept (Monetary) As Of Debit ifrs-full:LongtermDeposits
1240 Long-term deposits, interest rate Concept (Percent) As Of acst:LongtermDepositsInterestRate
1241 Deposits, interest rate Concept (Percent) As Of acst:DepositsInterestRate
1242 091 - Disclosure - Note 23 - Capital Management - Cash and Cash Equivalents (Details) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-23-capital-management-cash-and-cash-equivalents-details
1243 Statement Table [Table] Table

*

*

 acst:StatementTable
1244 Legal Entity [Axis] Axis dei:LegalEntityAxis
1245 Entity [Domain] Member dei:EntityDomain
1246 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1247 Cash Concept (Monetary) As Of Debit ifrs-full:Cash
1248 Cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashEquivalents
1249 Total Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
1250 092 - Disclosure - Note 24 - Subsequent Event (Details Textual) Network

*

*

 http://www.acastipharma.com/20180331/role/statement-note-24-subsequent-event-details-textual
1251 Statement Table [Table] Table

*

*

 acst:StatementTable
1252 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
1253 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
1254 Major ordinary share transactions [member] Member ifrs-full:MajorOrdinaryShareTransactionsMember
1255 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
1256 Counterparties [member] Member ifrs-full:CounterpartiesMember
1257 Underwriter [member] Member acst:UnderwriterMember
1258 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
1259 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
1260 Non-transferable broker warrants [member] Member acst:NontransferableBrokerWarrantsMember
1261 Broker warrants [member] Member acst:BrokerWarrantsMember
1262 Broker warrants expiring on May 9, 2023 [member] Member acst:BrokerWarrantsExpiringOnMay92023Member
1263 Broker warrants expiring on May 14, 2023 [member] Member acst:BrokerWarrantsExpiringOnMay142023Member
1264 Legal Entity [Axis] Axis dei:LegalEntityAxis
1265 Entity [Domain] Member dei:EntityDomain
1266 Statement Line Items [Line Items] LineItems acst:StatementLineItems
1267 Unit issued, price per unit Concept (Share) As Of acst:UnitIssuedPricePerUnit
1268 Proceeds from issuing units Concept (Monetary) For Period Debit acst:ProceedsFromIssuingUnits
1269 Proceeds from issuing units, net Concept (Monetary) For Period Debit acst:ProceedsFromIssuingUnitsNet
1270 Number of units issued during period Concept (Shares) For Period acst:NumberOfUnitsIssuedDuringPeriod
1271 Number of shares called by each warrant Concept (Shares) As Of acst:NumberOfSharesCalledByEachWarrant
1272 Exercise price, warrants issued Concept (Monetary) For Period acst:ExercisePriceWarrantsIssued
1273 Proceeds from issuing units, over-allotment option Concept (Monetary) For Period Debit acst:ProceedsFromIssuingUnitsOverallotmentOption
1274 Proceeds from issuing units, over-allotment option, net Concept (Monetary) For Period Debit acst:ProceedsFromIssuingUnitsOverallotmentOptionNet
1275 Number of units issued during period, over-allotment option Concept (Shares) For Period acst:NumberOfUnitsIssuedDuringPeriodOverallotmentOption
1276 Unit issued, price per unit, over-allotment option Concept (Share) As Of acst:UnitIssuedPricePerUnitOverallotmentOption
1277 Payments for cash commission, percent of gross proceeds Concept (Percent) For Period acst:PaymentsForCashCommissionPercentOfGrossProceeds
1278 Percent of warrants issued Concept (Percent) For Period acst:PercentOfWarrantsIssued
1279 Number of warrants issued during period Concept (Shares) For Period acst:NumberOfWarrantsIssuedDuringPeriod
1280 Number of shares called by warrants Concept (Shares) As Of acst:NumberOfSharesCalledByWarrants

*

*